A heterozygous-inactivating variant in PDE11A was identified in a non-secreting adrenocortical adenoma and heterozygous missense variants were more frequent in PBMAH (24%), ACA (19%), and ACC (16%) than in controls (5.7%) [39]. This evidence concerns the gene PDE11A and adrenal cortex carcinoma.